Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

NB-9402

Source date not recordedAnalyse record ↗

Second-generation covalent SARM1 inhibitor in first-in-human testing for a broader neuroprotective development program.

Modality
oral covalent irreversible allosteric small-molecule SARM1 inhibitor
Availability (US)
Phase 1a healthy-volunteer study underway; dosing initiated and completion expected in 2026
Biomarkers
safety, tolerability, pharmacokinetics, pharmacodynamics, and SARM1 target engagement
Hallmark targeted
mitochondrial dysfunction, NAD+ depletion, loss of proteostasis, neuronal degeneration
Kind
investigational drug
Clinical trials
Company-reported Phase 1a healthy-volunteer study